Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference Transcript

Core Insights - Vertex Pharmaceuticals provided an update on its T1D programs at the American Diabetes Association 85th Scientific Sessions, highlighting significant developments in their zimislecel therapy [2][3]. Company Overview - Susie Lisa, Senior Vice President of Investor Relations, emphasized the importance of the day for Vertex, marking it with the NEJM article release and the summer solstice [2]. Research and Development - Felicia Pagliuca, Senior Vice President of Cell and Genetic Therapy Research, is leading the discussion on the advancements in the company's research initiatives [4].